Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.
VO: Mid Caps Now Look Attractive, But Vanguard's $103 Billion ETF Misses The Mark
VO is a low-cost ETF offered by Vanguard, providing broad exposure to U.S. mid-cap stocks as defined by CRSP. However, CRSP Indexes allow overlap with the small/large-cap segments, impacting efficiency. As is common for Vanguard ETFs, VO will most likely deliver average category returns year to year, as it has done historically. However, it's not ideal from a fundamentals perspective. This article suggests combining XMHQ and XMMO to create a high-quality portfolio with strong momentum characteristics, potentially allowing for lesser drawdowns and faster recoveries.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
